Peer-reviewed veterinary case report
Oral oxaborole MRX-5 exhibits efficacy against pulmonaryin mouse.
- Journal:
- Antimicrobial agents and chemotherapy
- Year:
- 2024
- Authors:
- Rimal, Binayak et al.
- Affiliation:
- Department of Medicine · United States
Abstract
) is an opportunistic pathogen common in patients with lung comorbidities and immunosuppression. There are no FDA-approved treatments, and current treatment has a failure rate exceeding 50%. The intravenous oxaborole MRX-6038 is active against. This study evaluated MRX-5, the oral prodrug, against fiveisolates in a mouse lung infection model. MRX-5 showed dose-dependent efficacy, with 15 and 45 mg/kg doses comparable to the standard of care, supporting progression to clinical trial.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/39360824/